and crypto- Top Featured

Haineng Industry: The controlling shareholder intends to reduce the company's shares by no more than 3%;Shanghai builds a merger and reorganization head company, and Ning Wang magnifies the move. The bull market still needs to be believed.Shanghai's action plan for mergers and acquisitions is still very strong! Three years to cultivate 10 head companies, forming a scale of 300 billion mergers and acquisitions, which clearly accelerate the merger of securities companies and build a first-class investment bank. This is a semiconductor leader, a pharmaceutical leader, a new material leader, a brokerage leader, etc., which directly benefits Shanghai local stocks and pays attention to Shanghai's advantages. This time, the merger with assets exceeding 2 trillion is clearly activated, which shows great determination.

True Vision: The controlling shareholder and others intend to reduce their holdings by 4% in total;First, heavy! Shanghai merger and reorganization action plan announcedThis "moderately loose" statement the day before yesterday is definitely a major positive. Yesterday, A shares opened higher and went lower, but it was still expected to be too full! The high pressure level of 3500 was superimposed, so it dropped sharply. After-hours, the national society issued a document to interpret "moderate easing", and everyone understands the signal! This is a kind of expected management, which embodies the intention of caring for the economy and the stock market.

Before, I said that institutions don't believe in bull market, but now I don't believe in many sizes, so investors are doing their best to support the stock market. Now every time it goes up, bosses of all sizes are reducing their holdings, including big funds, which are frequently cashed out ...! This will hit everyone's confidence in holding shares.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.However, it is a great pity that the China stock market has never had a history of retail investors and institutions getting rich together. Don't deal with hot money and quantification! Foreign investment in A-shares has also become stale and has become fond of speculation. There are always too many routines to create A shares, which is too tiring to play, and the experience is really bad.